Promotion of Brulidine (dibrompropamidine isetionate) by Manx Healthcare Limited – December 2024
Published 20 January 2025
© Crown copyright 2025
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-december-2024/86bc7bf3-eb8b-4212-ae7c-ae2ae6021be3
The complainant contacted the MHRA about an advertisement for Brulidine (dibrompropamidine isetionate) that was allegedly published on LinkedIn on 26 July 2024 by Manx Healthcare Limited. Dibrompropamidine isetionate is an over-the-counter antiseptic and antibacterial cream.
The complainant alleged that the advertisement was not compliant with Part 14 (Advertising) of the Human Medicines Regulations 2012 due to the omission of the required statement for advertisements to the public to contain the invitation to read the Patient Information Leaflet (PIL) or label for further information about the medicine.
MHRA upheld the complaint. Manx Healthcare Limited responded to the complaint and said that they had amended the post to include the required statement in the advertisement in question. Further information on the requirements for advertisements of over-the-counter medicines to the public is provided in chapter 5 of the MHRA Blue Guide.